ASCO 2023 | ZUMA-7: overall survival benefit of axi-cel over SOC in second-line LBCL
Nirav Niranjan Shah
• 4 Jun 2023
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the overall survival (OS) benefit reported in the ZUMA-7 study (NCT03391466) comparing axicabtagene ciloleucel (axi-cel) to standard of care (SOC) in patients with large B-cell lymphoma (LBCL) in the second-line setting, highlighting the advantages of moving CAR-T in earlier lines of therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
